Aldevron Now Utilizing Berkeley Lights' Beacon® Platform
June 11, 2019 07:02 ET
|
Aldevron
Fargo, N.D., June 11, 2019 (GLOBE NEWSWIRE) -- Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic...
Aldevron Now Utilizing Berkeley Lights' Beacon® Platform
June 11, 2019 00:02 ET
|
Aldevron
Fargo, N.D., June 11, 2019 (GLOBE NEWSWIRE) -- Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic...
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
January 08, 2018 13:10 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...
AbCellera Announces Expanded Research Collaboration with Teva
June 13, 2017 09:00 ET
|
AbCellera
VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd....
AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
June 06, 2017 09:00 ET
|
AbCellera
VANCOUVER, British Columbia, June 06, 2017 (GLOBE NEWSWIRE) -- AbCellera has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines...
AbCellera Announces Multi-Target Research Collaboration with Pfizer
January 05, 2017 09:00 ET
|
AbCellera
VANCOUVER, British Columbia, Jan. 05, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Pfizer Inc. (NYSE:PFE). AbCellera...
AbCellera Completes Antibody Discovery Project With Kodiak Sciences to Identify Lead Therapeutic Candidates
August 24, 2016 09:00 ET
|
AbCellera
VANCOUVER, British Columbia, Aug. 24, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune...
AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria
July 20, 2016 09:00 ET
|
AbCellera
VANCOUVER, British Columbia, July 20, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune...
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
February 02, 2016 08:00 ET
|
AbCellera
JERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research...
AbCellera and Merck Sign Novel Therapeutic Antibody Discovery Collaboration
January 27, 2016 16:08 ET
|
AbCellera
VANCOUVER, British Columbia, Jan. 27, 2016 (GLOBE NEWSWIRE) -- AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today...